Table 2.
Multivariable Cox proportional hazards survival analysis in patients >80 years, by stage.
| Stage I/II | Stage III/IV | ||||||
|---|---|---|---|---|---|---|---|
| OS Analysis (n=523)1 | LRS Analysis (n=454)1 | OS Analysis (n=348)1 | LRS Analysis (n=298)2 | ||||
| Median OS (years)3 | HR (95% CI) | HR (95% CI) | Median OS (years)3 | HR (95% CI) | HR (95% CI) | ||
| Observation | 2.2 | Reference | Reference | Observation | 2.1 | Reference | Reference |
| CVP (≤ 4 cycles) | 1.3 | 1.00 (0.23–4.34) | 3.31 (0.68–16.03) | CVP (All cycles)4 | 1.3 | 0.92 (0.42–2.02) | 0.99 (0.35–2.86) |
| CVP (>4 cycles) | 1.9 | 1.38 (0.42–4.56) | 0.75 (0.10–5.80) | ||||
| CHOP (≤4 cycles) | 5.7 | 0.51 (0.21–0.89) | 0.79 (0.33–1.92) | CHOP (≤4 cycles) | 2.7 | 0.73 (0.36–1.49) | 0.47 (0.15–1.49) |
| CHOP (>4 cycles) | 6.9 | 0.37 (0.11–1.22) | 2.47 (0.70–8.66) | CHOP (>4 cycles) | 1.1 | 1.60 (0.44–5.78) | 2.63 (0.59–11.68)s |
| R-CVP (≤4 cycles) | 4.3 | 0.74 (0.48–1.15) | 1.02 (0.52–2.01) | R-CVP (≤4 cycles) | 3.9 | 0.67 (0.36–1.25) | 0.61 (0.23–1.64) |
| R-CVP (>4 cycles) | 4.5 | 0.60 (0.32–1.15) | 0.18 (0.02–1.34) | R-CVP (>4 cycles) | 6.9 | 0.33 (0.16–0.65) | 0.16 (0.05–0.57) |
| R-CHOP (≤4 cycles) | 6.4 | 0.50 (0.35–0.71) | 0.61 (0.34–1.09) | R-CHOP (≤4 cycles) | 3.3 | 0.67 (0.44–1.04) | 0.39 (0.20–0.77) |
| R-CHOP (>4 cycles) | 7.2 | 0.51 (0.34–0.77) | 0.59 (0.30–1.17) | R-CHOP (>4 cycles) | 6.1 | 0.39 (0.25–0.62) | 0.35 (0.18–0.72) |
1
B-symptoms were dropped due to complete separation across years of diagnosis.
2
B-symptoms and percentage in census tract completing high school dropped due to complete separation.
3
Median OS was unadjusted for covariates.
4
Only 1 patient with stage III/IV DLBCL was treated with >4 cycles of CVP.
Note: OS=overall survival, LRS=lymphoma-related survival; HR=hazard ratio; CI=confidence interval; CVP=cyclophosphamide, vincristine, prednisone; R-CVP=rituximab + CVP; CHOP=cyclophosphamide, doxorubicin, vincristine, prednisone; R-CHOP=rituximab + CHOP